**SINOVEDA TECHNOLOGY AND PIPILEINE**

**Technology for developing combination drugs:**

Sinoveda Canada Inc. adopts an innovative approach to drug discovery by starting with herbs that have a historical record of efficacy. This means that the company focuses on plant-based medicine with a proven track record in traditional medicinal practices. By combining this knowledge of historically effective herbs with their patented pharmaceutical platform technology (PPT), AI, and machine learning, Sinoveda aims to identify and develop novel combination therapies with high efficacy and safety profiles. This unique approach integrates traditional wisdom with cutting-edge technology to advance the drug discovery process and deliver promising new treatments.

**Long COVID Treatment:**

Long COVID has emerged as a post-pandemic crisis, with patients experiencing a range of symptoms such as fatigue, shortness of breath, and cognitive impairment, among others. However, there is hope on the horizon with the development of SCI-2213, a botanical pharmaceutical that could potentially provide relief to patients suffering from long COVID. Utilizing AI-assisted PPT, SCI-2213 comprises three active ingredients with anti-viral, anti-inflammatory, anti-fibrotic, anti-thrombotic, and immunomodulation properties.

Preliminary human observations have been encouraging, with 24 subjects with COVID and Long COVID responding positively to 11 symptoms within two days of treatment. However, further clinical trials are required to establish the safety and effectiveness of SCI-2213. The goal is to develop this botanical pharmaceutical into a safe and effective treatment for long COVID. To this end, a proper clinical trial is being planned to test the efficacy and safety of SCI-2213.

To ensure the sustainability of the supply chain for the consumer health product and the development of API, it's crucial to develop an infrastructure that can protect the supply of raw materials and the production of SCI-2213's active pharmaceutical ingredient. This will not only support the continued development of SCI-2213 but also help to establish a reliable supply chain that can meet the growing demand for treatments for long COVID.

**Cannabis Derived Cancer Treatments:**

*Pipeline:*A pipeline of candidates for the treatment of various types of cancer has been developed.  The leading candidates are for liver and colon cancer:

***Liver Cancer:*** Liver cancer is a significant global health concern, with an estimated 905,677 new cases and 830,180 deaths in 2020, making it the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths worldwide. Cannabis derived combination treatments for cancer have been gaining attention in recent years due to their potential therapeutic benefits. Two leading candidates, SCI-1172 and SCI-0502, have shown promise in preclinical studies as safe and effective treatment options for liver cancer. These combinations include three cannabinoids or sorafenib and one cannabinoid.  In in vitro clonogenic assays using patient-derived xenografts (PDXs) from three liver cancer patients, these combinations demonstrated efficacy and safety compared to sorafenib alone. Currently, these two candidates are being further tested in vivo using PDX from a liver cancer patient with the help of Kibur Medical's Inc's nanonail system to map out the effective concentrations in the patient tumour and mechanisms of action. The results of these studies could potentially pave the way for the development of new cannabis-derived cancer treatments that could provide patients with safer and more effective options.

***Colon Cancer:*** Colon cancer, also known as colorectal cancer, is a significant global health concern. It is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide, with an estimated 1.93 million new cases and 935,000 deaths in 2020.

Both SCI-1172 and SCI-0502 have shown promise in preclinical studies as potential treatments for colon cancer. Using patient-derived xenografts (PDXs) derived from colon cancer patients, these candidates will be tested in vivo with the help of Kibur’s technology. This testing will provide valuable insights into the safety and efficacy of these treatments for colon cancer, potentially paving the way for the development of new cannabis-derived combination therapies for this type of cancer.